Journal
NEURO-ONCOLOGY
Volume 22, Issue 6, Pages 773-784Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noaa036
Keywords
gliomas; immunotherapy; molecular-targeted therapy; neurofibromatosis type 1; pilocytic astrocytomas
Categories
Funding
- Gilbert Family Foundation [81-0810541, 0912232251]
Ask authors/readers for more resources
Gliomas are the most common primary central nervous system tumors occurring in children and adults with neurofibromatosis type 1 (NF1). Over the past decade, discoveries of the molecular basis of low-grade gliomas (LGGs) have led to new approaches for diagnosis and treatments. However, these new understandings have not been fully applied to the management of NF1-associated gliomas. A consensus panel consisting of experts in NF1 and gliomas was convened to review the current molecular knowledge of NF1-associated low-grade transformed and high-grade gliomas; insights gained from mouse models of NF1-LGGs; challenges in diagnosing and treating older patients with NF1-associated gliomas; and advances in molecularly targeted treatment and potential immunologic treatment of these tumors. Next steps are recommended to advance the management and outcomes for NF1-associated gliomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available